慢性炎性脱髓鞘性多发性神经病的诊治进展

Abstract
Figure/Table
References (29)
Related Citation (15)

Download: PDF (513 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated peripheral neuropathy characterized by weakness and sensory disturbances that may be associated with other neurological disorders. In addition to the classic CIDP, there are many variants which easily lead to misdiagnosis, so that improving the diagnosis of variant CIDP is very important. Diagnosis usually incorporates clinical manifestations, electrophysiological examinations, and other supporting evidence, such as nerve biopsy, somatosensory evoked potential, cerebral spinal fluid examination, MRI and ultrasound support evidence, CIDP first-line treatment including corticosteroid (CS), intravenous immunoglobulin (IVIg), plasma exchange (PE) and immunosuppressive treatment. The purpose of this study is to review the clinical manifestations, diagnosis and treatment of CIDP.

Key words： Chronic inflammatory demyelinating polyneuropathy Anomaly Diagnosis Treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Qi1 ZHAO Dongjie1 WANG Yuhua1 DONG Sha1 CHANG Lei1 ZHANG Peng1 NI Yao2
	3

Cite this article:

LI Qi1 ZHAO Dongjie1 WANG Yuhua1 DONG Sha1 CHANG Lei1 ZHANG Peng1 NI Yao2,3. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy[J]. 中国医药导报, 2018, 15(5): 37-40.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I5/37

[1] Mahdi-Rogers M，Hughes RA. Epidemiology of chronic inflammatory neuropathies in southeast England [J]. Eur J Neurol，2014，21（1）：28-33.
[2] Dimachkie MM，Saperstein DS. Acquired immune demyelinating neuropathies [J]. Continuum（Minneap Minn），2014， 20（5 Peripheral Nervous System Disorders）：1241-1260.
[3] 薛冰，刘沛东，张保朝，等.慢性吉兰-巴雷综合征102例临床分析[J].中国实用神经疾病杂志，2016，19（5）：36-38.
[4] Mcmillan HJ，Kang PB，Jones HR，et al. Childhood chronic inflammatory demyelinating polyradiculoneuropathy：combined analysis of a large cohort and eleven published series [J]. Neuromuscul Disord，2013，23（2）：103-111.
[5] Rinalduzzi S，Serafini M，Capozza M，et al. Stance Postural Strategies in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy [J]. PLoS One，2016，11（3）：e151629.
[6] Hattori N，Misu K，Koike H，et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy [J]. J Neurol Sci，2001，184（1）：57-63.
[7] Van den Bergh PY，Hadden RD，Bouche P，et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy：report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision [J]. Eur J Neurol，2010，17（3）：356-363.
[8] Kokotis P，Schmelz M，Papagianni AE，et al. Decreased Axon Flare Reaction to Electrical Stimulation in Patients With Chronic Demyelinating Inflammatory Polyneuropathy [J]. J Clin Neurophysiol，2017，34（2）：101-106.
[9] Gilmore KJ，Allen MD，Doherty TJ，et al. Electrophysiological and neuromuscular stability of persons with chronic inflammatory demyelinating polyneuropathy [J]. Muscle Nerve，2017，56（3）：413-420.
[10] Kang JH，Kim HJ，Lee ER. Electrophysiological evaluation of chronic inflammatory demyelinating polyneuropa thy and charcot-marie-tooth type 1：dispersion and correlation analysis [J]. J Phys Ther Sci，2013，25（10）：1265-1268.
[11] Tanaka K，Mori N，Yokota Y，et al. MRI of the cervical nerve roots in the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy：a single-institution，retrospective case-control study [J]. BMJ Open，2013，3（8）：e3443.
[12] Niu J，Cui L，Liu M. Multiple Sites Ultrasonography of Peripheral Nerves in Differentiating Charcot-Marie-Tooth Type 1A from Chronic Inflammatory Demyelinating Polyradiculoneuropathy [J]. Front Neurol，2017，8：181.
[13] Goedee HS，van der Pol WL，van Asseldonk JH，et al. Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies [J]. Neurology，2017，88（2）：143-151.
[14] Dyck PJ，Lais AC，Ohta M，et al. Chronic inflammatory polyradiculoneuropathy [J]. Mayo Clin Proc，1975，50（11）：621-637.
[15] 孙瑞迪，付斌，江军.短潜伏期体感诱发电位在慢性炎性脱髓鞘性多发性神经根神经病中的诊断作用[J].中国当代儿科杂志，2017，19（5）：545-548.
[16] Devic P，Petiot P，Mauguiere F. Diagnostic utility of somatosensory evoked potentials in chronic polyradiculopathy without electrodiagnostic signs of peripheral demyelination [J]. Muscle Nerve，2016，53（1）：78-83.
[17] Hiwatashi A，Togao O，Yamashita K，et al. Evaluation of chronic inflammatory demyelinating polyneuropathy：3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging（3D SHINKEI）[J]. Eur Radiol，2017，27（2）：447-453.
[18] 胡玉波，孔维涛.慢性炎性脱髓鞘性多发性神经根神经病神经系统的康复与治疗[J].河南医学研究，2017，26（18）：3327-3328.
[19] 卢希，沈雪莉.慢性吉兰-巴雷综合征应用激素的治疗分析[J].中国医学工程，2012，20（1）：62-63.
[20] Lucchetta M，Vidal E，Sartori S，et al. Long-term plasma exchange in pediatric CIDP [J]. J Clin Apher，2015，30（6）：364-366.
[21] Codron P，Cousin M，Subra JF，et al. Therapeutic plasma exchange in chronic dysimmune peripheral neuropathies：A 10-year retrospective study [J]. J Clin Apher，2017，32（6）：413-422.
[22] Nobile-Orazio E，Cocito D，Jann S，et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy：a randomised controlled trial [J]. Lancet Neurol，2012， 11（6）：493-502.
[23] Ellrichmann G，Gold R，Ayzenberg I，et al. Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy：efficacy of intravenous immunoglobulin treatment [J]. Ther Adv Neurol Disord，2017， 10（2）：91-101.
[24] Hughes RA，Donofrio P，Bril V，et al. Intravenous immune globulin（10% caprylate-chromatography purified）for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy（ICE study）：a randomised placebo-controlled trial [J]. Lancet Neurol，2008，7（2）：136-144.
[25] Lunn MP，Ellis L，Hadden RD，et al. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies [J]. J Peripher Nerv Syst，2016，21（1）：33-37.
[26] Nobile-Orazio E，Cocito D，Jann S，et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP [J]. J Neurol Neurosurg Psychiatry，2015，86（7）：729-734.
[27] Markvardsen LH，Christiansen I，Jakobsen J. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy [J]. Transfusion，2016，56（10）：2443-2448.
[28] Cocito D，Merola A，Peci E，et al. Subcutaneous immunoglobulin in CIDP and MMN：a short-term nationwide study [J]. J Neurol，2014，261（11）：2159-2164.
[29] Pitarokoili K，Yoon MS，Kroger I，et al. Severe refractory CIDP：a case series of 10 patients treated with bortezomib [J]. J Neurol，2017，264（9）：2010-2020.